Nil Albiol
@nilalbiol
Followers
289
Following
127
Media
23
Statuses
292
Hematologist | CAR-T cell Unit | @hospitalclinic, Barcelona | Focused in #CART/#CARTcell, #CLL, #Richter and #Lymphoma
Barcelona, Spain
Joined July 2014
📣SAVE THE DATE VII edición: "Aspectos prácticos en aplicación clínica de terapia Chimeric Antigen Receptor T-Cell (CAR-T)". 📅23-24 Oct 2025 📍Facultat de Medicina de la Universitat de Barcelona 🗣️Información e inscripciones: https://t.co/egMD0jiil5…
0
8
22
Drug development in MZL: caring for the forgotten child @BloodPortfolio @c_thieblemont #Sylvain Carras @ComeBommier
ashpublications.org
Marginal zone lymphoma (MZL) encompasses biologically heterogenous group of indolent B-cell lymphomas that remains substantially underrepresented in clinic
0
6
11
🇪🇸 var-cel in R/R FL academic anti-CD19 CAR T-cells N = 27 CRS all grades 55%, grade 3+ 4% 3-y PFS 81% Worth reading @Hemasphere_EHA ! https://t.co/ucTt8LUyq8
onlinelibrary.wiley.com
We report the outcome of patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with varnimcabtagene autoleucel (var-cel), an academic anti-CD19 chimeric antigen receptor (CAR)...
1
7
24
Our academic CAR-T (var-cel or ARI0001) from @hematoclinicbcn achieved similar efficacy to other CD19-directed products with a negligible ICANS incidence! It’s been a reality for almost 30 pts, most pf them remaining in CR to date. Congrats!
onlinelibrary.wiley.com
We report the outcome of patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with varnimcabtagene autoleucel (var-cel), an academic anti-CD19 chimeric antigen receptor (CAR)...
0
15
43
I will also present the results of a study evaluating the use of cell-free cfDNA MRD in CLL together with my great colleague @miguel_argdtom No. 1430 #iwCLL2025
0
4
21
Check out our poster on the results of varnimcabtagene autoleucel (ARI0001) in CLL and Richter’s transformation! Poster no. 1905 #iwCLL2025
6
10
66
Sure it is! Apply now!
#CRTH is just the perfect place to learn how to design a credible trial, connect with talented hematologists, and benefit from the insights of experienced mentors. We even take time to address work-life balance! If you’re interested, do not hesitate: apply before it’s too late!
0
0
4
CONGRESS | #SOHO2025 | PRESENTATION @niravshahmd @MedicalCollege presents phase Ia results from the phase I NX-5948-301 trial of bexobrutideg (NX-5948) in patients with R/R CLL/SLL (N = 48). Bexobrutideg was well tolerated, and responses were rapid, with an ORR of 80.9%, a median
0
2
3
CONGRESS | #EHA2025 | POSTER Juan Du, Shanghai Changzheng Hospital, presents updated phase I results on 1L BCMA-CD19 dual CAR-T therapy in transplant-eligible high-risk NDMM (N=22). Median FU=37.1 months. High response rates: ORR and MRD-neg=100%; sCR=95%. Median DoR not reached.
1
5
11
Two patients had autoimmune hemolytic anemia that relapsed after CD19 CAR T-cell therapy but responded rapidly to BCMA-targeted T-cell–engager therapy with remission, minimal side effects, and hematologic improvement. Learn more: https://t.co/Jhni7W8897
0
13
44
Happy to present two posters about molecular MRD in AML at #EHA2025 in Milan. Check them out at today’s poster session!
0
1
35
📢 EHA 2025 Board Election Results 📢 We are pleased to announce the results of the EHA 2025 Board elections. After a thorough and democratic process, we welcome our newly elected Board members, who will serve from 2025 to 2029, helping to shape the future of hematology and
0
1
19
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
ashpublications.org
Key PointsDespite having relatively favorable disease kinetics, patients with relapsed/refractory BL who receive CAR T cells have poor outcomes.Future tria
0
3
4
Academic CART cell Myeloma #ARI0002h #CART25 @fdezdelarrea @hematoclinicbcn @TheEBMT @hospitalclinic
0
11
36
CONGRESS | #CART25 | PRESENTATION Carlos Fernández de Larrea @fdezdelarrea @hospitalclinic highlights results from a study of ARI0002h in patients with R/R multiple myeloma, and discusses the potential impact of academic point-of-care CAR T-cell manufacturing on access to CAR
0
6
21
@EHA_Hematology You will not find a more interesting and exciting experience in #clinicalresearch training in #hematology. @EHA_Hematology #CRTH is the best educational program for early stage career hematologists. Stay tuned for the next call in June 2025!!
0
5
18
I’m very happy to be part of the #CRTH @EHA_Hematology The first workshop at Milan has been wonderful so far, with great faculty team that have helped me a lot to improve my project. Also met some great people there, we had a great time together! See you at #EHA2025
0
2
25
@nilalbiol (@hematoclinicbcn) es el único hematólogo español que está participando en esta edición de @EHA_Hematology #CRTH. Excelente trabajo y gran progreso a lo largo del workshop 1. ¡Felicidades! Deseando ver progresos en la reunión de #EHA2025. @sehh_es @SEHHJoven
1
7
14
Happy to share our comprehensive study on non-hematologic autoinmune disorders in CLL patients at #ASH24 Expansion of IL-17-F producing cells mediated by IL23 may explain lower risk of leukemic progression. Come to discuss our results at 5:30pm 🙂
1
5
49